Glutamate-cysteine ligase and Glutathione synthetase (GCL/GSS)

The glutathione synthetic pathway is a critical two-step enzymatic process responsible for the production of glutathione (GSH), the most abundant non-protein thiol and a primary antioxidant in eukaryotic cells (Lu, 2013, Biochimica et Biophysica Acta). The pathway begins with the rate-limiting enzyme glutamate-cysteine ligase (GCL), which catalyzes the formation of gamma-glutamylcysteine from glutamate and cysteine, followed by glutathione synthetase (GSS), which adds glycine to complete the tripeptide (PubChem). These enzymes play a pivotal role in maintaining cellular redox homeostasis and detoxifying reactive oxygen species and electrophilic compounds (NIH). In many cancers, the expression of GCL and GSS is elevated, providing a mechanism for resistance against oxidative stress-inducing therapies like radiation and certain chemotherapies (Traverso et al., 2013, Oxidative Medicine and Cellular Longevity). Conversely, genetic or acquired deficiencies in these enzymes lead to increased susceptibility to oxidative damage, contributing to neurodegenerative diseases and hemolytic anemia (StatPearls). Pharmacological intervention often targets GCL with inhibitors like buthionine sulfoximine (BSO) to sensitize tumor cells, or utilizes precursors like N-acetylcysteine to bolster GSH levels in inflammatory or toxic states (PubMed).

Other names

Glutathione synthetic pathwayGSH biosynthetic enzymesGamma-glutamyl cycle enzymesGlutamate-cysteine ligase catalytic subunitGlutamate-cysteine ligase regulatory subunit

Inhibition of the rate-limiting enzyme glutamate-cysteine ligase to deplete glutathione or provision of precursors to enhance synthesis.